Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vancomycin, quantity: 1000 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins. severe staphylococcal (including methicillin resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg strep. faecalis), effective only in combination with an aminoglycoside. diphtheroid endocarditis. in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia, and soft itssue infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin injections. should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c difficile). parenteral administration alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral adminsitration, the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudo-membranous colitis.

United States - English - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj), famtozinameran (unii: jsv288q5cv) (famtozinameran - unii:jsv288q5cv) - pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5) is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 12 years of age and older. this eua prescribing information pertains only to pfizer-biontech covid-19 vaccine, bivalent (original and omicron ba.4/ba.5), hereafter referred to as pfizer-biontech covid-19 vaccine, bivalent. do not administer pfizer-biontech covid-19 vaccine, bivalent to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the pfizer-biontech covid-19 vaccine or the pfizer-biontech covid-19 vaccine, bivalent [see description (13)] . risk summary no data are available regarding the use of pfizer-biontech covid-19 vaccine, bivalent during pregnancy. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, t

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - monobasic potassium phosphate, quantity: 136.1 mg/ml - injection, concentrated - excipient ingredients: water for injections - treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. the cause of hypophosphataemia should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 2 mg/ml (equivalent: noradrenaline (norepinephrine), qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium metabisulfite; sodium chloride; water for injections - for the restoration of blood pressure in certain acute hypotensive states (e.g phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - minoxidil, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; colloidal anhydrous silica - indications as at 1 january 1991 : indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. when used in combination with an accompanying diuretic and beta-blocker, minoxidil (loniten) has been shown to reverse encephalopathy and retinopathy in severe hypertensives.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - varenicline tartrate, quantity: 1.71 mg (equivalent: varenicline, qty 1 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400; indigo carmine aluminium lake; triacetin - champix is indicated as an aid for smoking cessation in adults over the age of 18 years

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - varenicline tartrate, quantity: 1.71 mg (equivalent: varenicline, qty 0.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400; indigo carmine aluminium lake; triacetin - champix is indicated as an aid for smoking cessation in adults over the age of 18 years

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - piroxicam, quantity: 10 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; maize starch; magnesium stearate - feldene is indicated for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.